JAN 20, 2019 04:13 PM PST

Multiple sclerosis treatments hold long-term benefits

WRITTEN BY: Nouran Amin

An international study, led by the Clinical Outcomes Research unit (CORe) at Royal Melbourne Hospital and University of Melbourne, concludes the importance of early treatments of multiple sclerosis (particularly within the first five years of onset) holds extensive long-term benefits.

Learn more about Multiple Sclerosis (MS):

The study was the first to provide evidence that current drug treatments delay the progression of multiple sclerosis (MS) into its secondary stage which is described by an ongoing increase of disability involving the worsening of physical and mental capacity as well as the reduced quality of life. The crucial need to delay the progression represents an important outcome for individuals living with multiple sclerosis.

The research generated data from 1555 patients at 68 neurological clinics across 21 countries and highlighted the importance to treat MS pro-actively.

Multiple sclerosis is a condition characterized by areas of damage on the brain. This damage affects the covering that protects nerves (the myelin sheath).

Credit: NIH Genetics Home Reference

"People who converted from relapsing MS to secondary progressive MS experience gradual and mostly irreversible worsening of disability,” said Associate Professor and head of the MS Service at The Royal Melbourne Hospital and CORe at the University of Melbourne, Tomas Kalincik."Most of the therapies that we use to treat MS have no effect once people have converted to secondary progressive MS. This study shows us how important it is to treat relapsing MS early and pro-actively," Associate Professor Kalincik said.

Results of the study, in collaboration with the University of Cambridge, were published in the international medical journal, JAMA. Associate Professor Kalincik believes that the results are reassuring neurologists and patients with MS. He states, "This study shows that the therapies they have been treated with for many years, significantly improve the quality of their lives over the long-term.”

Source: The Royal Melbourne Hospital

 

About the Author
  • Nouran enjoys writing on various topics including science & medicine, global health, and conservation biology. She hopes through her writing she can make science more engaging and communicable to the general public.
You May Also Like
OCT 22, 2019
Drug Discovery & Development
OCT 22, 2019
Can Ecstasy Treat PTSD and Depression?
Ecstasy, also known as MDMA or “molly”, is a well-known substance known to induce feelings of euphoria and bliss, followed by a notorious, depr...
OCT 22, 2019
Drug Discovery & Development
OCT 22, 2019
Chemotherapeutics react differently to radiation
Patients with various types of cancer are almost always treated with a combination of chemotherapy and radiotherapy. In chemotherapy, therapeutics consist ...
OCT 22, 2019
Technology
OCT 22, 2019
How Bitcoins Can Advance Medication Usage
Will futuristic concepts from the world of technology likely find a place in our medicine cabinet? Maybe! The new concept has been known as ‘cryptoph...
OCT 22, 2019
Drug Discovery & Development
OCT 22, 2019
Adderall is Almost Identical to Crystal Meth
Adderall has a reputation for giving people a feeling of euphoria, increasing energy levels and enhancing abilities to focus and concentrate. And coinciden...
OCT 22, 2019
Neuroscience
OCT 22, 2019
Can CRISPR Technology Treat Alzheimer's?
New drugs that seek to treat Alzheimer’s disease (AD) have a 99.6% failure rate. This makes it the only disease in the top 10 causes of death that ca...
OCT 22, 2019
Health & Medicine
OCT 22, 2019
All you need to know about Orphan Drugs
Orphan drugs are medicinal products intended for the diagnosis, prevention, or treatment of very rare life-threatening diseases. To offset the high development cost of orphan drugs, in 1983,...
Loading Comments...